Search

Now showing items 1-10 of 14

Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

Covid-19 Vaccine Protection among Children and Adolescents in Qatar.

Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Nature Research , 2022 , Article)

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...

Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals

Shurrab, Farah M; Younes, Nadin; Al-Sadeq, Duaa W; Liu, Na; Qotba, Hamda; ... more authors ... less authors ( Elsevier , 2022 , Article)

The vast majority of the commercially available LFIA is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based LIFA test was developed for quantitative measurement of the total binding ...

Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2 IgG antibodies using advanced detection assays.

Shurrab, Farah M; Al-Sadeq, Duaa W; Amanullah, Fatima Humaira; Al-Absi, Enas S; Qotba, Hamda; ... more authors ... less authors ( Karger , 2022 , Report)

Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point of care (POC) rapid testing kits. However, some rapid ...

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...

Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics

Makhoul, Monia; Abou-Hijleh, Farah; Seedat, Shaheen; Mumtaz, Ghina R.; Chemaitelly, Hiam; ... more authors ... less authors ( springer nature , 2022 , Article)

Background: Prospective observational data show that infected persons with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain polymerase chain reaction (PCR) positive for a prolonged duration, and that ...

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Ahmed, Zaqout; Almaslamani, Muna A.; Chemaitelly, Hiam; Hashim, Samar A.; Ittaman, Ajithkumar; ... more authors ... less authors ( Elsevier , 2022 , Article)

ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ...

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

Shurrab, Farah M.; Al-Sadeq, Duaa W.; Abou-Saleh, Haissam; Al-Dewik, Nader; Elsharafi, Amira E.; ... more authors ... less authors ( MDPI , 2022 , Report)

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was ...

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

Qassim, Suelen H.; Hasan, Mohammad R.; Tang, Patrick; Chemaitelly, Hiam; Ayoub, Houssein H.; ... more authors ... less authors ( Frontiers Media , 2022 , Article)

In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ...